Scientists have discovered vital clues to help predict, more than a decade in advance, which men may develop prostate cancer.

A Florida surgeon remotely performed robotic prostate removal on a 66-year-old cancer patient from about 35 miles away as ...

The patient was at a facility in Minneola, Florida, while the surgeon operated remotely from another facility ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

The FDA has expanded its approval of talazoparib in combination with enzalutamide to include men with metastatic androgen ...

It’s true. As of last Saturday, October 24, there is a new once-daily prostate cancer drug that can reduce or eliminate prostate tumors, according to Johnson & Johnson’s early-stage trial.

Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction ...

University Hospitals research suggests the Decipher tumor score could help doctors personalize treatment decisions for men ...

Jessie J shared she’s “healing” after undergoing her second breast cancer reconstruction surgery one year after the first: ...

Key Stats for Johnson & Johnson StockPrice change for Johnson & Johnsonstock in the last 6 months: 16%$JNJ Stock Price as of Oct. 23: $26452-Week High: $281$JNJ Stock Price Target: $279__Now Live: ...

Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated ...

TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps ...